FDA nanotechnology draft guidance represents ‘marginal progress’ – petition group
date:May 10, 2012
A to issue more than just voluntary guidance on the issue.


Marginal progress


The campaigners, which are all currently working on nanotechnology oversight, have called on the FDA to further the so-far marginal progress toward regulation of products made with this new technology.


The draft guidance followed a lawsuit filed in December 2011 by the group, regarding the FDAs failure to respond to their 2006 petition. The FDA responded to the groups lawsuit in April 2012.


In its formal respons
3/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
12/29 03:32